You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.


Treatment x

While the holidays are a time to celebrate with family and friends, the season can quickly go from joyful to stressful for women and men with breast cancer, whether they're trying to juggle holiday responsibilities or struggling with social expectations.

Since 1989, breast cancer deaths have declined by 40 percent—a statistic that can be attributed in large part to advances in treatment.

Photo of several vials of IV drugs

Over the last 50 years, we have seen breast cancer treatment evolve from a single approach to more personalized treatments that focus on the characteristics of the tumor and the patient.


Breast cancer deaths have declined dramatically in recent decades and are nearly 40 percent below their peak in the late 1980s. While this trend may be partially attributed to improvements in screening and early detection, treatment advances play an even larger role.

A new type of drug is now approved for certain patients with metastatic breast cancer. Olaparib (Lynparza®) belongs to a class of drugs called PARP inhibitors.


Dr. Angela Hartley Brodie, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of Medicine passed away from complications of Parkinson's Disease on June 7. She was 82.


Women diagnosed with larger tumors, typically stage II- III, may receive chemotherapy prior to surgery – called neoadjuvant therapy–to reduce the size of the tumor, which can allow for less extensive and breast conserving surgery.  


Post mastectomy radiation therapy (PMRT) is commonly recommended for women with stage I-III breast cancer to prevent local recurrence.